A paradigm shift in the prevention of retinopathy of prematurity

Neonatology

Volumn 100, Issue 2, 2011, Pages 116-129

  Raghuveer, Talkad S ^a   Bloom, Barry T ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Extremely low birth weight infants; Oxygen saturation; Retinopathy of prematurity; Vascular endothelial growth factor

Indexed keywords

ALPHA TOCOPHEROL; ERYTHROPOIETIN; GLUCOSE; OMEGA 3 FATTY ACID; OXYGEN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; VASCULOTROPIN;

BREAST MILK; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DISEASE MARKER; DISEASE SEVERITY; EXTREMELY LOW BIRTH WEIGHT; GLUCOSE BLOOD LEVEL; HIGH RISK INFANT; HUMAN; HYPERGLYCEMIA; HYPEROXIA; NONHUMAN; OXYGEN SATURATION; OXYGEN THERAPY; PATHOGENESIS; PHOTOPIC VISION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD VESSEL; RETINA DISEASE; RETINAL VESSEL LOSS; RETINOPATHY; RETROLENTAL FIBROPLASIA; REVIEW; VITAMIN SUPPLEMENTATION;

ALGORITHMS; HUMANS; INCIDENCE; INFANT, NEWBORN; INFANT, PREMATURE; OXYGEN; RETINOPATHY OF PREMATURITY; RISK FACTORS;

EID: 79952101414     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000322848     Document Type: Review

References (112)

1. Terry TL: Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am J Opthalmol 1942; 25: 203-206.
2. Gilbert C, Foster A: Childhood blindness in the context of VISION 2020 - the right to sight. Bull World Health Organ 2001; 79: 227-232. (Pubitemid 32246481)
3. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A, on behalf of the International NO-ROP Group. Pediatrics 2005; 115:e518-e525.
4. The EXPRESS Group: One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301: 2225-2233.
5. Stoll BJ, Hansen NI, Bell EF, et al: Neonatal outcomes of extremely preterm infants from the NICHD Research Network. Pediatrics 2010; 126: 443-456.
6. Vermont Oxford Database Project 2005- 2008 Annual Reports: Burlington, Vermont Oxford Network, 2009.
7. Slidsborg C, Olesen HB, Jensen PK, et al: Treatment for retinopathy of prematurity in Denmark in a ten-year period (1996-2005): Is the incidence increasing? Pediatrics 2008; 121: 97-105.
8. Hoogerwerf A, Schalij-Delfos NE, van Schooneveld MJ, Termote JUM: Incidence of retinopathy of prematurity over the last decade in the Central Netherlands. Neonatology 2010; 98: 137-142.
9. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B: Incidence and early course of retinopathy of prematurity: The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991; 98: 1628-1640.
10. Early Treatment for Retinopathy of Prematurity Cooperative Group: The incidence and course of retinopathy of prematurity: Findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005; 116: 15-23.
11. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group: The Early Treatment for Retinopathy of Prematurity Study; structural findings at age 2 years. Br J Ophthalmol 2006; 90: 1378-1382. (Pubitemid 44702064)
12. O'Connor AR, Stephenson T, Johnson A, et al: Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics 2002; 109: 12-18. (Pubitemid 34051330)
13. Msall ME, Phelps DL, DiGaudio KM, et al: Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years. Pediatrics 2000; 106: 998-1005.
14. Schmidt B, Asztalos EV, Roberts RS, Robertson CMT, Sauve TS, Whitfield MF: Impact of bronchopulmonary dysplasia, brain injury and severe retinopathy of prematurity on the outcome of extremely low birth weight infants at 18 months. JAMA 2003; 289: 1124-1129. (Pubitemid 37430326)
15. Msall ME, Phelps DL, Hardy RJ, et al: Educational and social competencies at 8 years in children with threshold retinopathy of prematurity in the CRYO-ROP multicenter study. Pediatrics 2004; 113: 790-799. (Pubitemid 38437385)
16. Chen J, Smith LE: Retinopathy of prematurity. Angiogenesis 2007; 10: 133-140. (Pubitemid 46440629)
17. Chan-Ling T, Gock B, Stone J: The effect of oxygen on vasoformative cell division: Evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995; 36: 1201-1214.
18. Stone J, Itin A, Alon T, et al: Development of retinal vasculature is mediated by hypoxiainduced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-4747.
19. Pierce EA, Avery RI, Foley ED, Aiello LP, Smith LE: Vascular endothelial growth factor/ vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-909.
20. Kinsey VE, Zacharias L: Retrolental fibroplasia: Incidence in different localities in recent years and a correlation of the incidence with treatment given the infants. J Am Med Assoc 1949; 139: 572-578.
21. Campbell K: Intensive oxygen therapy as a possible cause of retrolental fibroplasia: A clinical approach. Med J Aust 1951; 2: 48-50.
22. Patz A, Hoeck LE, De La Cruz E: Studies on the effect of high oxygen administration in retrolental fibroplasia: Nursery observations. Am J Ophthalmol 1952; 35: 1248-1253.
23. Lanman JT, Guy LP, Dancis J: Retrolental fibroplasia and oxygen therapy. J Am Med Assoc 1954; 155: 223-226.
24. Kinsey VE: Retrolental fibroplasia: Cooperative study of retrolental fibroplasias and the use of Oxygen. Arch Ophthalmol 1956; 56: 481-543.
25. James S, Lanman JT: History of oxygen therapy and retrolental fibroplasia. Prepared by the American Academy of Pediatrics, Committee on Fetus and Newborn with the collaboration of special consultants. Pediatrics 1976; 57(suppl 2):591-642.
26. Avery ME: Recent increase in mortality from hyaline membrane disease. J Pediatr 1960; 57: 553-559.
27. Duc G, Sinclair JC: Oxygen administration; in Sinclair JC, Bracken MB (eds): Effective Care of the Newborn Infant. Oxford, Oxford University Press, 1992, pp 178-199.
28. Flynn JT, Bancalari E, Snyder ES, et al: A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326: 1050-1054.
29. Aoyagi T, Kishi M, Yamaguchi K, Watanabe S: Improvement in earpiece oximeter (in Japanese). Abstracts of the 13th Annual meeting of the Japan Society of MEBE, 1974, pp 90- 91.
30. Hay WW Jr, Brockway J, Eyzaguirre M: Neonatal pulse oximetry: Accuracy and reliability. Pediatrics 1989; 83: 717-722. (Pubitemid 19120513)
31. Tin W, Milligan DW, Pennefather P, Hay E: Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84:F106-F110. (Pubitemid 32250852)
32. Chow LC, Wright KW, Sola A: Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 2003; 111: 3309-3345.
33. VanderVeen DK, Mansfield TA, Eichenwald EC: Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS 2006; 10: 445-448. (Pubitemid 44633728)
34. Saugstad OD: Optimal oxygenation at birth and in the neonatal period. Neonatology 2007; 91: 319-322. (Pubitemid 46934218)
35. Finer N, Leone T: Oxygen saturation monitoring for the preterm infant: The evidence basis for current practice. Pediatr Res 2009; 65: 375-380.
36. Chen ML, Guo L, Smith LEH, Dammann CEL, Dammann O: High or low oxygen saturation and severe retinopathy of prematurity: A meta-analysis. Pediatrics 2010; 125: E1483-e1492.
37. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, et al: Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 363: 1959-1969.
38. Clucas L, Doyle LW, Dawson J, Donath S, Davis PG: Compliance with alarm limits for pulse oximetry in very preterm infants. Pediatrics 2007 119: 1056-1060. (Pubitemid 46871258)
39. Hagadorn JI, Ferey AM, Nghiem TH, Schmid CH, Phelps DL, Pillers DA, Cole CH, Aviox Study Group: Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks gestation: The AVIOX study. Pediatrics 2006; 118: 1740-1741.
40. Claure N, D'Ugard C, Banacalari E: Automated adjustment of inspired oxygen in preterm infants with frequent fluctuations in oxygenation: A pilot clinical trial. J Pediatr 2009; 155: 640-645.
41. Leone TA, Rich W, Finer NN: A survey of delivery room resuscitation practices in the United States. Pediatrics 2006; 117:e164-e175. (Pubitemid 46071570)
42. Finer N, Saugstad O, Vento M, Barrington K, Davis P, Duara S et al: Use of oxygen for resuscitation of extremely low birth weight infant. Pediatrics 2010; 125: 389-391.
43. Fisher JW: Erythropoietin: Physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228: 1-14. (Pubitemid 36077622)
44. Chen J, Connor KM, Aderman CM, Smith LE: Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118: 526-533. (Pubitemid 351206543)
45. Patel S, Rowe MJ, Winters SA, Ohls RK: Elevated erythropoietin mRNA and protein concentrations in the developing human eye. Pediatr Res 2008; 63: 394-397. (Pubitemid 351450585)
46. Widness JA, Seward VJ, Kromer IJ, Burmeiser LF, Bell EF: Changing patterns of red blood cell transfusion in very low birth infants. J Pediatr 1996; 129: 680-687. (Pubitemid 27498277)
47. Suk KK, Dunbar JA, Liu AL, Daher NS, Leng CK, Leng JK, Lim P, Weller S, Fayard E: Human recombinant erythropoietin and the incidence of retinopathy of prematurity: A multiple regression model. J AAPOS 2008; 12: 233-238. (Pubitemid 351853461)
48. Brown MS, Baron AE, France EK, Hamman RF: Association between higher cumulative doses of recombinant of erythropoietin and risk of retinopathy of prematurity. J AAPOS 2006; 10: 143-149.
49. Shah N, Jadav P, Jean-Baptiste D, Weedon J, Cohne LM, Kim MR: The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Amer J Perinatol 2010: 27: 67-71.
50. Schneider JK, Gardner DK, Cordero L: Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low birth weight infants. Pharmacotherapy 2008; 28: 1335-1340.
51. Hellström A, Perruzzi C, Ju M, et al: Low IGF-1 suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001; 98: 5804-5808. (Pubitemid 32435723)
52. Hellström A, Svensson E, Carlssson B, Niklasson A, Albertsson-Wikland K: Reduced retinal vascularization in children with growth hormone deficiency. J Clin Endocrinol Metab 1999; 84: 795-798. (Pubitemid 29075723)
53. Langford K, Nicolaides K, Miell JP: Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimesters of human pregnancy. Hum Reprod 1998; 13: 1389-1393. (Pubitemid 28279201)
54. Lineham JD, Smith RM, Dahlenburg GW, King RA, Haslam RR, Stuart MC, Faull L: Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally. Early Hum Dev 1986; 13: 37-46. (Pubitemid 16124142)
55. Hellstrom A, Engstrom E, Hard AL, et al: Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy and other complications of premature birth. Pediatrics 2003; 112: 1016-1020. (Pubitemid 37339551)
56. Diaz-Gomez NM, Domenech E, Barroso F: Breast feeding and growth factors in preterm newborn infants. J Pediatr Gastroenterol Nutr 1997; 24: 322-327. (Pubitemid 27199622)
57. Elmlinger MW, Grund R, Buck M, Wollmann HA, Feist N, Weber MM, Speer CP, Ranke MB: Limited proteolysis of the IGF binding protein-2 (IGFBP-2) by a specific serine protease activity in early breast milk. Pediatr Res 1999; 46: 76-81. (Pubitemid 29293900)
58. Hansen-Pupp I, Engstrom E, Niklasson A, et al: Fresh frozen plasma as a source of exogenous insulin-like growth factor I in the extremely preterm infant. J Clin Endocrinol Metab 2009; 94: 477-482.
59. Lofqvist C, Niklasson A, Engstrom E, et al: A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGFbinding protein-3 complex to preterm infants. Pediatr Res 2009; 65: 574-579.
60. Vanhaesebrouck S, Daniels H, Moons L, Vanhole C, Carmeliet P, De Zegher F: Oxygen- induced retinopathy in mice: Amplication by neonatal IGF-1 deficit and attenuation by IGF-1 administration. Pediatr Res 2009; 65: 307-310.
61. Okamoto N, Okamoto N, Tobe T, et al: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neonvascularization. Am J Pathol 1997; 151: 281-291.
62. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP: Vascular endothelial growth factor is sufficient to produce iris neo-vascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964-970. (Pubitemid 26271462)
63. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neo-vascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
64. Sato T, Kusaka S, Shimojo H, Fujikado T: Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009; 116: 1599-1603.
65. The STOP-ROP Multicenter Study Group: Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I. Primary outcomes. Pediatrics 2000; 105: 295-310.
66. Hay WW, Bell EF: Oxygen therapy, oxygen toxicity and STOP-ROP trial. Pediatrics 2000; 105: 424-425. (Pubitemid 30078689)
67. Askie LM, Henderson-Smart D, Irwig L, Margaret-Simpson J: Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003; 349: 959-967. (Pubitemid 37064769)
68. Watanabe D, Suzuma K, Matsui S, et al: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353: 782-792. (Pubitemid 41215487)
69. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LEH: Suppression of retinal neo-vascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 1329-1335.
70. Morita M, Ohneda O, Yamashita T, et al: HLF/HIF-2 α is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 2003; 22: 1134-1146. (Pubitemid 36313597)
71. Bierer R, Peceny MC, Hartenberger CH, Ohls RK: Erythropoietin concentrations and neuro-developmental outcome in preterm infants. Pediatrics 2006; 118:e635-e640. (Pubitemid 46089988)
72. Slusarski JD, McPherson RJ, Wallace GN, Juul SE: High dose of erythropoietin does not exacerbate retinopathy of prematurity in rats. Pediatr Res 2009; 66: 625-630.
73. Gaynon MW: Rethinking STOP-ROP: Is it worthwhile trying to modulate excessive VEGF levels in prethreshold eyes by systemic intervention? Retina 2006; 26:S18-S23.
74. Dani C, Reali MF, Bertinin G, Martelli E, Pezzati M, Rubaltelli FF: The role of blood transfusions and iron intake on retinopathy of prematurity. Early Hum Dev 2001; 62: 57-63. (Pubitemid 32178136)
75. Englert JA, Saunders RA, Purohit D, Hulsey TC, Ebeling M: The effect of anemia on retinopathy of prematurity in extremely low birth weight infants. J Perinatol 2001; 21: 21-26. (Pubitemid 33710850)
76. Smith LE, Shen W, Perruzzi C, et al: Regulation of vascular endothelial growth factordependent retinal neo-vascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-1395.
77. Frank L, Groseclose EE: Preparation of birth into an O 2 -rich environment: The antioxidant enzymes in the developing rabbit lung. Pediatr Res 1984; 18: 240-244. (Pubitemid 14166124)
78. Gutcher GR, Raynor WJ, Farrell PM: An evaluation of vitamin E status in premature infants. Am J Clin Nutr 1984; 40: 1078-1089. (Pubitemid 15210588)
79. Saugstad OD: Oxidative stress in the newborn: A 30 year perspective. Biol Neonate 2005: 88: 228-236. (Pubitemid 41433555)
80. Saugstad OD, Rognum TO: High postmortem levels of hypoxanthine in the vitreous humor of premature babies with respiratory distress syndrome. Pediatrics 1988; 81: 395-398. (Pubitemid 18096801)
81. Owens WC, Owens EU: Retrolental fibroplasia in premature infants. II. Studies on the prophylaxis of the disease: The use of alpha tocopheryl acetate. Am J Ophthalmol 1949; 32: 1631-1637.
82. Raju TNK, Langenberg P, Bhutani V, Quinn G: Vitamin E prophylaxis to reduce retinopathy of prematurity: A reappraisal of published trials. J Pediatr 1997; 131: 844-850. (Pubitemid 28027608)
83. Brion LP, Bell EF, Raghuveer TS: Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003;CD003665.
84. Johnson L, Quinn GE, Abbasi S, et al: Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: A controlled clinical trial. J Pediatr 1989; 114: 827-838. (Pubitemid 19122985)
85. Connor KM, SanGiovanni JP, Lofqvist C, et al: Increased dietary intake of ω -3 polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007; 7: 868-873. (Pubitemid 47038185)
86. Birch EE, Carlson SE, Hoffman DR, et al: The DIAMOND (DHA intake and measurement of neural development) Study: A double masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid. Am J Clin Nutr 2010; 91: 848-859.
87. Smithers LG, Gibson RA, McPhee A, Makrides M: Higher dose of docosahexaenoic acid in the neonatal period improves visual acuity of preterm infants: Results of a randomized controlled trial. Am J Clin Nutr 2008; 88: 1049-1056.
88. Kollias AN, Ulbig MW: Diabetic retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl Int 2010; 107: 75-83.
89. Kermorvant E, Lavalette S, Guillonneau X, Houssier M, Raoul W, Chemtob S, Sennlaub F: Neonatal hyperglycemia induce retinal vaso-obliteration and neuronal degeneration: Implications for retinopathy of prematurity. PAS 2010, abstr 3125.3.
90. Binder ND, Raschko, PK, Benda GI, Reynolds JW: Insulin infusion with parenteral nutrition in extremely low birth weight infants with hyperglycemia. J Pediatr 1989; 114: 273-280. (Pubitemid 19059125)
91. Farrag HM, Cowett RM: Glucose homeostasis in the micropremie. Clin Perinatol 2000; 27: 1-22. (Pubitemid 30109062)
92. Mitanchez-Mokhtari, Lahlou N, Kieffer F, Magny JF, Roger M, Voyer M: Both relative insulin resistance and defective islet β -cell processing of proinsulin are responsible for transient hyperglycemia in extremely preterm infants. Pediatrics 2004; 113: 537-541. (Pubitemid 38280794)
93. Garg R, Agthe AG, Donohue PK, Lehmann CL: Hyperglycemia and retinopathy of prematurity in very low birth weight infants. J Perinatol 2003: 23: 186-194. (Pubitemid 36656517)
94. Blanco CL, Baillargeon JG, Morrison RL, Gong AK: Hyperglycemia in extremely low birth infants in a predominantly Hispanic population and related morbidities. J Perinatol 2006; 26: 737-741. (Pubitemid 44811507)
95. Glass P, Avery GB, Subramanian KN, Keys MP, Sostek AM, Friendly DS: Effect of bright light in the hospital nursery on the incidence of retinopathy of prematurity. N Engl J Med 1985; 313: 401-404. (Pubitemid 15014034)
96. Wesolowski E, Smith LEH: Effect of light on oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 112-119. (Pubitemid 24046833)
97. Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WAJ, Fielder AR: Lack of efficacy of light reduction in preventing retinopathy of prematurity. N Engl J Med 1998; 338: 1572-1576. (Pubitemid 28243986)
98. Chan-Ling T, Bisti S, Maccarone R, Yun S: Rationale for non-invasive treatment of ROP: Dark rearing minimizes vaso-obliteration during hyperoxia and mimics physiological vascularisation (poster presentation). Association for Research in Vision and Ophthalmology Annual Meeting, May 2009, Fort Lauderdale. Invest Ophthalmol Vis Sci 2009; 50:abstr 3121.
99. Cringle SJ, Yu DY, Yu PK, Su EN: Intraretinal oxygen consumption in the rat in vivo. Invest Ophthalmol Vis Sci 2002; 43: 1922-1927. (Pubitemid 34587042)
100. Wagner J, Jan Danser AH, Derkx FH, et al: Demonstration of renin MRA, angiotensinogen mRNA and angiotensin converting enzyme RNA expression in the human eye: Evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996; 80: 159-163. (Pubitemid 26058551)
101. Wheeler-Schilling TH, Kohler K, Sautter M, Guenther E: Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci 1999; 11: 3387-3394. (Pubitemid 29484235)
102. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Betram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL: Retinal neo-vascularization is prevented by blockade of reninangiotensin system. Hypertension 2000; 36: 1099-1104.
103. Mauer M, Zinman B, Gardiner R, et al: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
104. Yokota H, Nagaoka T, Mori F, et al: Prorenin levels in retinopathy of prematurity. Am J Ophthalmol 2007; 143: 531-533.
105. Lahera V, Giochoechea M, de Vinuesa SG, et al: Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Curr Med Chem 2007; 14: 243-248. (Pubitemid 46043919)
106. Bartoli M, Al-Shabrawey M, Labazi M, et al: HMG-CoA reductase inhibitors (statin) prevents retinal neo-vascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 4934-4940.
107. Lofqvist C, Andersson E, Sigurdsson J, et al: Longitudinal postnatal weight and Insulin- like Growth Factor-1 measurements in the prediction of Retinopathy of Prematurity. Arch Opthalmol 2006; 124: 1711-1718. (Pubitemid 44913194)
108. Lofqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LEH, Ley D, Hellstrom A: Validation of a new retinopathy of prematurity screening method monitoring longitudinal weight gain and insulin-like growth factor I. Arch Opthalmol 2009; 127: 622-627.
109. Hellstrom A, Hard AL, Engstrom E, et al: Early weight gain predicts retinopathy in preterm infants: New, simple, efficient approach to screening. Pediatrics 2009; 123:e638-e645.
110. Wu C, VanderVeen DK, Hellstrom A, Lofqvist C, Smith LEH: Longitudinal postnatal weight measurements for prediction of retinopathy of prematurity. Arch Ophthalmol 2010; 128: 443-447.
111. Hausprurg AK, Allred EN, Vanderveen DK, et al: Blood gases and retinopathy of prematurity: The ELGAN study. Neonatology 2010; 99: 104-111.
112. Mintz-Hittner HA, Kennedy KA, Chuag AZ, for the BEAT-ROP Cooperative Group: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-615.